Semaglutide "GLP-1 Injection" "Medical Weight Loss"

Product information

$286.00

Intro and pharmacokinetics: Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA). GLP-1Ras have been commercially available since 2005 with medications such as lixisenatide, exenatide, albiglutide, dulaglutide, and liraglutide. Semaglutide was approved by the FDA for treatment of type 2 diabetes in 2017 (Ozempic) and for obesity management in 2021 (Wegovy). Semglutide is currently the only GLP-1RA that is available in both a subcutaneously injectable and oral formulation. Semaglutide is structurally 94% homologous to native human GLP-1, with modifications at positions 8, 26, and 34 to prolong its half-life. Semaglutide works by mimicking the GLP-1 hormone that causes your pancreas to release insulin, blocks your liver from making glucose, and slows down how quickly food leaves your stomach. It also works in the areas of the brain that regulate appetite and fullness. It has a mean time to reach maximum serum concentration (Tmax) of 36 hours (24-72 h) and a half-life (t ½) of 167±13.2 hours. For this reason, it is typically dosed once weekly. For comparison, naturally occurring GLP-1 has a half-life of approximately 2 minutes. Dosing: Dose Initial starting dose is 0.25mg/wk. After that, the dose is increased to 0.5mg/wk. The dose can be further increased to 1.0mg/wk and up based on an individuals response and speed of weight loss. Oral semaglutide is administered once daily at doses of 7 and 14mg, with an initial introductory dose of 3mg for the first 30 days. Side effects: Side effects from semaglutide are usually rare and manageable, though can occur if the dose is advanced too rapidly. This is why this medication is started at such a small dose to begin with. • nausea; • diarrhea; • constipation; • gas and bloating; • fatigue • pain where the medicine was injected. In short: In addition to reduced energy intake, likely mechanisms for semaglutide-induced weight loss included less appetite and food cravings, better control of eating and lower relative preference for fatty, energy-dense foods. Essentially, when taking semaglutide, you don’t get hungry as often, you feel full quicker, and you have fewer cravings. Average weight loss on semaglutide was 1-1.5 lbs per week. Resources: Tilinca MC, Tiuca RA, Niculas C, et al. Future perspectives in diabesity treatment: semaglutide, a glucagon‑like peptide 1 receptor agonist (Review). Exp Ther Med. 2021;22(open in a new window). doi:10.3892/etm.2021.10601 Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(open in a new window):7370–7380. doi:10.1021/acs.jmedchem.5b00726 Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;104(open in a new window):31–41. doi:10.1016/j.ejps.2017.03.020 Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(open in a new window):1242–1251. doi:10.1111/dom.12932 Nauck MA, Gallwitz B, Seufert J. Semaglutide- pharmacodynamic and pharmacokinetic characteristics of a new long-acting GLP-1-receptor agonist. Diabetol Stoffwechs. 2017;12(open in a new window):135–140. doi:10.1055/s-0043-104866

In stock

Intro and pharmacokinetics: Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA). GLP-1Ras have been commercially available since 2005 with medications such as lixisenatide, exenatide, albiglutide, dulaglutide, and liraglutide. Semaglutide was approved by the FDA for treatment of type 2 diabetes in 2017 (Ozempic) and for obesity management in 2021 (Wegovy). Semglutide is currently the only GLP-1RA that is available in both a subcutaneously injectable and oral formulation. Semaglutide is structurally 94% homologous to native human GLP-1, with modifications at positions 8, 26, and 34 to prolong its half-life. Semaglutide works by mimicking the GLP-1 hormone that causes your pancreas to release insulin, blocks your liver from making glucose, and slows down how quickly food leaves your stomach. It also works in the areas of the brain that regulate appetite and fullness. It has a mean time to reach maximum serum concentration (Tmax) of 36 hours (24-72 h) and a half-life (t ½) of 167±13.2 hours. For this reason, it is typically dosed once weekly. For comparison, naturally occurring GLP-1 has a half-life of approximately 2 minutes. Dosing: Dose Initial starting dose is 0.25mg/wk. After that, the dose is increased to 0.5mg/wk. The dose can be further increased to 1.0mg/wk and up based on an individuals response and speed of weight loss. Oral semaglutide is administered once daily at doses of 7 and 14mg, with an initial introductory dose of 3mg for the first 30 days. Side effects: Side effects from semaglutide are usually rare and manageable, though can occur if the dose is advanced too rapidly. This is why this medication is started at such a small dose to begin with. • nausea; • diarrhea; • constipation; • gas and bloating; • fatigue • pain where the medicine was injected. In short: In addition to reduced energy intake, likely mechanisms for semaglutide-induced weight loss included less appetite and food cravings, better control of eating and lower relative preference for fatty, energy-dense foods. Essentially, when taking semaglutide, you don’t get hungry as often, you feel full quicker, and you have fewer cravings. Average weight loss on semaglutide was 1-1.5 lbs per week. Resources: Tilinca MC, Tiuca RA, Niculas C, et al. Future perspectives in diabesity treatment: semaglutide, a glucagon‑like peptide 1 receptor agonist (Review). Exp Ther Med. 2021;22(open in a new window). doi:10.3892/etm.2021.10601 Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(open in a new window):7370–7380. doi:10.1021/acs.jmedchem.5b00726 Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;104(open in a new window):31–41. doi:10.1016/j.ejps.2017.03.020 Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(open in a new window):1242–1251. doi:10.1111/dom.12932 Nauck MA, Gallwitz B, Seufert J. Semaglutide- pharmacodynamic and pharmacokinetic characteristics of a new long-acting GLP-1-receptor agonist. Diabetol Stoffwechs. 2017;12(open in a new window):135–140. doi:10.1055/s-0043-104866

Product options